Drugs / TGI-5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07376707 | Jun 2025 → Oct 2027 expected | colorectal cancer, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma | Hefei TG ImmunoPharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGI-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07376707 ↗ |
| Route | Intravenous | “TGI-5 at the assigned dose regimen (intravenous \[IV\] infusion)” NCT07376707 ↗ |